Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
On Thursday, H.C. Wainwright reiterated its Buy rating and $30.00 price target for Voyager Therapeutics (NASDAQ:VYGR) stock. This affirmation comes in the wake of the company’s fourth-quarter 2024 earnings report, which showcased ongoing advancements in its gene therapy (GT) and biologics programs for neurological diseases. According to InvestingPro data, analysts maintain a strong bullish consensus on VYGR, with price targets ranging from $9 to $30, suggesting significant upside potential from current levels around $4.06.
Voyager Therapeutics reported that it remains financially robust, with sufficient capital to continue operations into mid-2027. InvestingPro analysis confirms this strong financial position, showing the company holds more cash than debt and maintains a healthy current ratio of 5.56. The company’s strategic partnerships with Neurocrine (NASDAQ:NBIX) Biosciences (NBIX; Buy; Fein), Novartis (SIX:NOVN) (NVS; not rated), and Alexion (NASDAQ:ALXN), a subsidiary of AstraZeneca (NASDAQ:AZN; not rated), are significant. These collaborations could yield potential milestone payments totaling up to $8.2 billion.
The firm’s analysts highlighted upcoming events that are expected to act as key catalysts for Voyager. Notably, additional non-human primate data on VY1706, a tau silencing gene therapy, is set to be presented at the Alzheimer’s & Parkinson’s Disease (ADPD 2025) Conference, scheduled for April 1-5 in Vienna, Austria. Furthermore, the company plans to file Investigational New Drug (IND) applications in 2025 for its GBA1 Parkinson’s and Friedreich’s ataxia gene therapy programs, in partnership with Neurocrine.
Voyager Therapeutics is also eagerly anticipating the second half of 2026 for the release of tau PET imaging data from the Phase 1b multiple ascending dose study of VY7523, an anti-tau antibody. This data is expected to provide validation for the company’s tau-targeting approach in the treatment of Alzheimer’s disease.
The firm believes that Voyager’s robust pipeline, coupled with multiple imminent catalysts and its unique gene therapy platform, positions the company to generate significant value for its shareholders. InvestingPro analysis indicates the stock is currently undervalued, trading at a modest price-to-book ratio of 0.75. For deeper insights into VYGR’s valuation and growth potential, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Voyager Therapeutics released its fourth-quarter 2024 earnings report, revealing an earnings per share (EPS) of -0.37, which met analysts’ expectations. However, the company did not disclose its revenue forecast. Despite the earnings miss, Voyager maintains a strong cash position of $332 million, with a cash runway extending to mid-2027, bolstered by substantial potential future milestone payments totaling $8.2 billion. Truist Securities reaffirmed their Buy rating for Voyager Therapeutics with a consistent price target of $18.00, highlighting confidence in the company’s prospects despite recent challenges. Meanwhile, Citi adjusted its price target for Voyager to $11.00 from $12.00 but maintained a Buy rating, noting the company’s ongoing efforts in developing treatments for Alzheimer’s disease. Voyager’s recent updates include promising safety data for its VY7523 anti-Tau antibody, which is part of its Alzheimer’s treatment development. The company also plans to present additional data on VY7523 and initial preclinical data for its VY1706 Tau silencing gene therapy at an upcoming conference. Voyager’s partnerships, such as those with Neurocrine Biosciences and Novartis, are expected to contribute non-dilutive revenue, further extending its financial runway.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.